v3.26.1
Cover Page
Sep. 01, 2026
Document Information [Line Items]  
Document Type POS AM
Entity Registrant Name BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 256 E. Grand Avenue
Entity Address, Address Line Two Suite 104
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Tax Identification Number 39-3690783
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 405-4770
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Entity Small Business true
Entity Ex Transition Period false
Amendment Flag true
Entity Central Index Key 0001869105
Amendment Description On August 29, 2025, BridgeBio Oncology Therapeutics, Inc. (the “Company”) filed a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) on Form S-1 (File No. 333-289940) (the “Registration Statement”), which was initially declared effective by the SEC on September 10, 2025. This Post-Effective Amendment No. 2 to Form S-1 on Form S-3 (this “Post-Effective Amendment”) to the Registration Statement is being filed to convert the Registration Statement into a registration statement on Form S-3. The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement on August 29, 2025.
Business Contact [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 256 E. Grand Avenue
Entity Address, Address Line Two Suite 104
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 405-4770
Contact Personnel Name Pedro J. Beltran